T3 Dosing Protocols: Cytomel and Compounded Liothyronine

What Is Liothyronine (T3) and Why Is It Prescribed?

Liothyronine is the biologically active thyroid hormone that binds directly to nuclear receptors in nearly every cell in the body. The thyroid gland secretes mostly thyroxine (T4), which peripheral tissues then convert to T3 via deiodinase enzymes. When that conversion is impaired, supplementing T3 directly can resolve symptoms that persist despite normal TSH on levothyroxine alone.

The American Thyroid Association's 2012 guidelines acknowledged that "a subset of hypothyroid patients may benefit from combination T4 + T3 therapy," while stopping short of recommending it universally. A 2019 systematic review in the European Journal of Endocrinology (N=1,216 across six trials) found that combination therapy improved quality-of-life scores and psychological well-being in roughly 47% of participants compared with T4-only treatment. [1]

Cytomel (King Pharmaceuticals) is the brand-name tablet available in 5 mcg, 25 mcg, and 50 mcg strengths. Compounded liothyronine, prepared by 503A or 503B licensed pharmacies, expands dosing flexibility, allowing 2.5 mcg increments, sustained-release capsule formulations, and tablet strengths not commercially available. The FDA does not approve compounded preparations, but the agency allows them under specific conditions when a prescriber documents medical necessity. [2]

Standard T3 Dosing Protocols for Cytomel

Starting low matters. Abrupt T3 loading can provoke palpitations, atrial fibrillation, or angina, particularly in patients over 60 or those with pre-existing cardiovascular disease.

Monotherapy (T4 replacement not tolerated or absent thyroid)

The standard outpatient starting dose is 5 mcg orally once or twice daily. After 1 to 2 weeks, the clinician reassesses resting heart rate, symptom burden, and free T3. Dose increases proceed in 5-mcg steps, typically every 2 to 4 weeks, targeting a free T3 in the upper half of the reference range (roughly 3.1, 4.4 pg/mL in most lab assays). Typical maintenance sits between 25 to 75 mcg/day in divided doses. [3]

Myxedema coma (inpatient protocol)

This is a different clinical scenario entirely. Intravenous liothyronine is given at 10 to 20 mcg IV every 8 to 12 hours until the patient is stable, then transitioned to oral therapy. The endocrine society's guidance recommends concurrent hydrocortisone 100 mg IV every 8 hours to prevent adrenal crisis triggered by the metabolic surge. [4]

Cancer suppression dosing

Differentiated thyroid cancer survivors on TSH-suppression therapy may receive liothyronine 75 to 100 mcg/day to maintain TSH <0.1 mIU/L during radioiodine preparation, when levothyroxine must be withdrawn. The short half-life of T3 (roughly 1 day vs. T4's 7 days) means it clears faster before scanning, reducing the hypothyroid burden time from 6 weeks to approximately 2 weeks. [5]

Compounded Liothyronine: Sustained-Release Formulations and Custom Doses

Standard Cytomel tablets release T3 rapidly. Serum free T3 peaks 2 to 4 hours after ingestion and returns to baseline by 8 to 12 hours, which is why twice-daily (or even three-times-daily) dosing is physiologically more accurate than once-daily. Some patients report afternoon energy crashes that correlate exactly with this pharmacokinetic dip.

Compounding pharmacies can encapsulate liothyronine with a sustained-release matrix (commonly hydroxypropyl methylcellulose) to flatten that peak and extend the T3 exposure curve over 12 to 16 hours. A 2013 randomized crossover study published in the Journal of Clinical Endocrinology and Metabolism (N=46) found that sustained-release T3 produced steadier serum concentrations with fewer palpitations than immediate-release T3, while achieving comparable TSH suppression. [6]

Common compounded liothyronine preparations and why clinicians choose them:

• 2.5 mcg capsules for fine-grained titration when adding T3 to existing levothyroxine
• 5 mcg/5 mcg sustained-release capsules dosed twice daily as a Cytomel alternative
• Combination T3/T4 capsules (e.g., 7.5 mcg T3 + 75 mcg T4) that mirror natural desiccated thyroid ratios
• Sublingual troches for patients with malabsorption conditions affecting oral bioavailability

Bioavailability of oral liothyronine runs approximately 95%, making it one of the most predictably absorbed oral drugs in endocrinology. Compounded capsules may vary slightly by pharmacy, so patients switching formulations should recheck free T3 within 4 to 6 weeks. [7]

Levothyroxine Dosing by Weight: The Standard T4 Protocol

Levothyroxine (T4) remains the first-line hormone replacement for most patients with primary hypothyroidism. The American Association of Clinical Endocrinologists (AACE) recommends a weight-based starting dose of 1.6 mcg/kg of ideal body weight per day for patients with complete thyroid failure (post-thyroidectomy or late Hashimoto's). [8]

In practice, the formula works like this: a 70-kg adult with no residual thyroid function needs approximately 112 mcg/day. Because levothyroxine comes in fixed tablet strengths (25, 50, 75, 88, 100, 112, 125, 137, 150, 175 to 200 mcg), the prescriber rounds to the nearest available strength.

Partial function (subclinical or early overt hypothyroidism) typically needs only 1.0 to 1.2 mcg/kg/day because residual gland output covers the gap. Elderly patients over 65, those with cardiac disease, and postmenopausal women generally start at 25 to 50 mcg/day regardless of weight and titrate slowly, checking TSH every 6 to 8 weeks. [9]

Absorption matters. Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before food, coffee, or calcium-containing products. Co-administration with cholestyramine, calcium carbonate, ferrous sulfate, or proton pump inhibitors can reduce absorption by 30 to 40%. [10]

Levothyroxine vs. Natural Desiccated Thyroid: Conversion and Comparison

Natural desiccated thyroid (NDT, sold as Armour Thyroid, NP Thyroid, and Nature-Throid) is derived from porcine thyroid glands. Each grain (60 to 65 mg) contains approximately 38 mcg T4 and 9 mcg T3, giving a T4:T3 ratio of roughly 4.2:1 by weight. [11]

Conversion table:

| NDT dose | Approximate T4 equivalent | |----------|--------------------------| | 0.5 grain (30 mg) | 50 mcg levothyroxine | | 1 grain (60 mg) | 100 mcg levothyroxine | | 1.5 grains (90 mg) | 150 mcg levothyroxine | | 2 grains (120 mg) | 200 mcg levothyroxine |

These conversions are approximate. Because NDT contains a fixed and relatively high T3 fraction, some patients transitioning from levothyroxine find they need a slightly lower grain dose than the table suggests to avoid T3 excess symptoms (heart racing, sweating, anxiety). A safe transition strategy is to start at 80% of the equivalent NDT dose and recheck free T3, free T4, and TSH at 6 weeks.

A 2019 randomized trial by Idrees et al. in the Journal of Clinical Endocrinology and Metabolism (N=70) found 49% of participants preferred NDT over levothyroxine at 12-month follow-up, and the NDT group lost an average of 4 pounds more despite equivalent TSH levels. The mechanism is not fully established but may relate to the direct T3 content. [12]

The AACE/ATA joint statement notes that NDT "is not currently recommended as first-line therapy" due to the supraphysiologic T3 spike following ingestion, but concedes individual patient preference is a legitimate clinical consideration. [13]

The HealthRX Thyroid Optimization Framework guides clinicians through a stepwise decision process: (1) confirm primary vs. central hypothyroidism, (2) assess deiodinase polymorphism risk (DIO2 Thr92Ala variant, present in approximately 12 to 16% of the population), (3) select monotherapy or combination therapy, (4) choose immediate-release or sustained-release T3 preparation based on the patient's cardiovascular risk profile, and (5) set individualized TSH, free T4, and free T3 target ranges rather than defaulting to population-wide midpoints.

Adding T3 to Existing Levothyroxine: Step-by-Step Protocol

Many patients on stable levothyroxine continue to report fatigue, brain fog, weight resistance, and mood disturbances despite a TSH within normal range. Before adding T3, the prescriber should confirm free T3 sits in the lower third of the reference range (below approximately 2.8 pg/mL), rule out other causes (iron deficiency, sleep apnea, cortisol dysregulation), and document informed consent regarding the off-label use. [14]

Protocol steps:

1. Reduce levothyroxine by 25 to 50 mcg to create T4 space.
2. Add liothyronine 5 mcg in the morning (or 2.5 mcg twice daily using a compounded preparation).
3. Wait 4 weeks. Check free T3, free T4, TSH, and resting heart rate.
4. If free T3 remains below target and no cardiac symptoms are present, increase liothyronine by 2.5 to 5 mcg and reassess.
5. Most patients stabilize between 10 to 25 mcg/day of total added T3.
6. Recheck bone density (DXA) annually if free T3 is maintained above the midpoint of normal in postmenopausal women or men over 65.

The physiologic T4:T3 secretion ratio from a healthy thyroid is approximately 14:1 by moles, but peripheral conversion makes the cellular ratio closer to 4:1 to 5:1 in most tissues. Targeting that ratio when combining levothyroxine and liothyronine doses gives a reasonable pharmacologic starting point. [15]

Adjusting Levothyroxine in Pregnancy

Pregnancy changes thyroid hormone requirements substantially. The placenta expresses high levels of type 3 deiodinase, which inactivates T3 and T4, and hCG stimulates TSH receptors during the first trimester, temporarily lowering maternal TSH. Simultaneously, estrogen-driven increases in thyroxine-binding globulin raise total T4 requirements.

The Endocrine Society's 2017 Clinical Practice Guideline on thyroid disease in pregnancy recommends increasing levothyroxine by 25 to 30% as soon as pregnancy is confirmed, often by taking two additional tablets per week immediately (e.g., moving from 100 mcg daily to 100 mcg five days per week plus 150 mcg two days per week). TSH should be rechecked every 4 weeks during the first half of pregnancy and at least once between weeks 26, 32. [16]

Target TSH ranges during pregnancy (Endocrine Society 2017):

• First trimester: 0.1, 2.5 mIU/L
• Second trimester: 0.2, 3.0 mIU/L
• Third trimester: 0.3, 3.0 mIU/L

Poorly controlled hypothyroidism in the first trimester is associated with reduced fetal IQ by 3, 5 points and a doubling of preterm birth risk, per a study in the New England Journal of Medicine (Lazarus et al., N=21,846). [17] After delivery, requirements typically return to pre-pregnancy levels within 6 weeks, so a post-partum TSH check prevents iatrogenic hyperthyroidism.

T3 (liothyronine) monotherapy is not recommended in pregnancy. The placenta does not transfer T3 efficiently, and the fetus depends on maternal T4 for its own T3 production during the first 12 weeks before fetal thyroid function begins. [16]

Monitoring Parameters and Safety Considerations

T3 excess carries meaningful risks. Atrial fibrillation risk rises significantly when TSH is suppressed below 0.1 mIU/L; a meta-analysis in Circulation (N=10 studies, combined N>60,000) found subclinical hyperthyroidism with TSH <0.1 mIU/L was associated with a hazard ratio of 1.31 (95% CI 1.19, 1.46) for atrial fibrillation. [18] Bone mineral density loss also accelerates with chronic T3 excess, with annual trabecular bone loss of up to 1.3% reported in postmenopausal women on TSH-suppressive doses.

Monitoring schedule for patients on T3-containing regimens:

• TSH, free T3, free T4: at baseline, at 4 to 6 weeks after any dose change, then every 6 to 12 months once stable
• Resting heart rate and blood pressure: at each visit
• ECG: at baseline in patients over 60 or with cardiovascular risk factors
• DXA bone density: at baseline and every 1 to 2 years in high-risk groups
• Liver function: not routinely required but considered if symptoms suggest hepatic involvement

Interactions to flag: amiodarone blocks T4-to-T3 conversion and raises serum T4 while lowering T3; lithium inhibits thyroid hormone synthesis and secretion; oral contraceptives raise thyroxine-binding globulin, increasing total T4 requirements. [19]

Who Is a Candidate for Compounded vs. Brand-Name T3?

Cytomel suits patients who need standard doses (5, 25, or 50 mcg) and respond well to twice-daily dosing without cardiovascular side effects. Compounded liothyronine suits a narrower but real group: patients requiring 2.5 mcg increments for fine titration, those who experience peak-related palpitations and want sustained-release, patients with tablet swallowing difficulty, and those whose prescribers document a specific medical need for a formulation unavailable commercially.

The FDA's 2019 guidance on thyroid compounding noted that commercially available liothyronine products "are generally adequate for most patients," but the agency did not restrict access to compounded versions for patients with documented clinical need. [20] Compounded products prepared by an accredited 503B outsourcing facility carry the closest equivalence to FDA manufacturing oversight, and prescribers should verify pharmacy accreditation through the PCAB (Pharmacy Compounding Accreditation Board) database before prescribing.

Cost is a practical factor. Cytomel 5 mcg tablets (100-count) retail at approximately $60, $90 without insurance. Compounded liothyronine from a 503A pharmacy typically runs $30, $55 per month for equivalent daily doses, though formulation quality varies by compounder.

Dosing Pitfalls Clinicians See Most Often

Taking T3 once daily in a single large dose is the most common prescribing error. A single 25 mcg morning dose produces a free T3 peak 3 to 4 hours later that may cause palpitations or anxiety, followed by sub-therapeutic trough levels by evening. Splitting the dose into morning and early afternoon administrations or switching to a sustained-release compounded capsule resolves this in most cases.

A second recurring problem: failing to reduce levothyroxine when adding T3. Each 5 mcg of liothyronine added without removing some T4 raises the total thyroid hormone load. For every 5 mcg of T3 added, reducing levothyroxine by 25 mcg approximates hormonal neutrality at the cellular level. [15]

Third: checking only TSH when monitoring T3 therapy. TSH can be appropriately suppressed to the lower end of normal in a patient on combination therapy without representing clinical hyperthyroidism. Free T3 and free T4 must both be in range. Treating a low-normal TSH in isolation often causes under-dosing and persistent symptoms.